Pain, PostoperativePhase 4NCT01711229
Equality Study of Ofirmev vs Oral Acetaminophen
A Phase 4 study testing IV acetaminophen and oral acetaminophen in people with Pain, Postoperative, run by Babiash, Kimberly H., M.D. at 1 site in United States.
Trial summary
Acetaminophen (Tylenol) is a drug that is used commonly for relief of mild to moderate pain. It is found in many pain medicines that people take after having surgery. Narcotics are other drugs also used for pain (examples of narcotics are morphine and related pain medications). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Pain, Postoperative
- What is being tested?
- IV acetaminophen and oral acetaminophen
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 114 participants
- Where
- 1 siteUnited States
- Study dates
- Dec 2015to Dec 2016
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥18
- Weight 75kg -120 kg
- Undergoing arthroscopic rotator cuff repair by same surgeon at Surgicare of Wichita
- Patients who sign informed consent
- Patients who do not meet any of the exclusion criteria
Who cannot join
- Age < 18 yrs (will reduce risk of overdosing oral acetaminophen)
- History of opioid abuse or chronic opioid use greater than 3 months (may skew data with regards to pain control due to the concept of tolerance)
- Acetaminophen allergy (avoids risk of allergic reaction)
- Liver disease as determined by anesthesiologist by history (acetaminophen involves the liver for metabolism, therefore, if the liver is not functioning appropriately, doses could accumulate and cause damage.)
- Daily alcohol consumption (same explanation as for liver disease)
- Renal failure (patient on dialysis or health history indicates renal dysfunction) (acetaminophen has some renal excretion)
Show all 17Show fewer
- Asthma (recent concerns for acetaminophen leading to asthma exacerbations)
- Any other contraindication to taking acetaminophen
- Surgeon requested pre-operative Interscalene block (this will cause the patient to cease having pain, therefore the effects of acetaminophen reducing pain scores will not be able to be evaluated)
- Current warfarin, carbamazepine, or phenytoin use (these medications can accumulate in the presence of excessive acetaminophen use or may harm the liver and affect acetaminophen use or may harm the liver and affect acetaminophen concentrations).
- Weight greater than 120 kg (1.5 gram doses of acetaminophen may be too low to appropriately evaluate the effects in this patient population)
- Patients scheduled for "possible rotator cuff repair" (including these patients in our studies could skew enrollment numbers should a rotator cuff repair not be done, so these patients will be screened and excluded prior to enrollments)
- Any consumption of acetaminophen containing products in the 24 hour period prior to surgery (excluded because acetaminophen can induce its own metabolism, therefore reducing serum concentrations)
- Any significant medical disease(s), laboratory abnormalities or condition(s) that in the Investigator's judgment could compromise the subject's welfare, ability to communicate with the study staff, complete study activities, or would otherwise contraindicate study participation.
- Non-English speaking patients
- Patients who are not able to consent for themselves.
- pregnant patients (All female patients of childbearing potential are given a pregnancy test prior to any elective surgery at Surgicare. Though acetaminophen is NOT harmful to these patients, they will be excluded given the fact that elective surgery in itself is contraindicated in pregnancy)
Trial locations and contacts
1 site in 1 country.
United States1 site
Surgicare of Wichita
Wichita, Kansas, 67208
Gerry Bassell, MD, 316-685-2207
Kimberly H Babiash, MD
About this study
Official title: Prospective Randomized Equivalence Trial Comparing the Analgesic Efficacy of Ofirmev® Compared to a 1.5 Gram Dose of Oral Acetaminophen for Arthroscopic Rotator Cuff Repair
Acetaminophen (Tylenol) is a drug that is used commonly for relief of mild to moderate pain. It is found in many pain medicines that people take after having surgery. Narcotics are other drugs also used for pain (examples of narcotics are morphine and related pain medications). Medical science knows for a fact that acetaminophen works well when taken with narcotics for moderate to severe pain. Recently, acetaminophen has become available in an intravenous (IV) form called Ofirmev®. The IV form means that acetaminophen can be given into a vein. The benefits of getting medicine from an IV include:
- making the medicine work quickly
- less medicine having to pass through the liver to be changed into a form that your body can process The investigators know that acetaminophen is helpful for pain relief at the time of surgery and after surgery. Acetaminophen is a very popular drug in outpatient surgery for pain control when patients go home. The patient's surgeon uses it to control pain after surgery at home in the form of Lortab or Percocet (Lortab and Percocet also have a narcotic medicine that mixes with acetaminophen). Also, currently at Surgicare, some anesthesiologists give intravenous acetaminophen while the patient is waiting to go to surgery. The investigators currently do not give any patient acetaminophen by mouth BEFORE surgery. However, since the addition of the IV form to the drug market, there has been interest to see if the oral form is just as good or better in reducing pain after surgery. This is why we are asking patients to join our study. The goal of this study is to find out if the oral form (by mouth) or the IV form (given into a vein) of acetaminophen controls pain after surgery better.
Read the detailed description
The American Society of Anesthesiologists recommends acetaminophen, NSAIDS, or COX-2 inhibitors as part of a multimodal pain management strategy to limit opioid usage (1). As the surgical patient population becomes more complex with comorbidities ranging from obesity, obstructive sleep apnea , and asthma becoming more common, the medical community continues to search for efficacious analgesics with a high safety profile. While non-steroidal anti-inflammatory drugs play an important role in multi-modal analgesia, their use is limited based on concerns for platelet inhibition, asthma exacerbation, and renal artery perfusion in patients of advanced age or reduced creatinine clearance.
Acetaminophen has proven to be an important analgesic in the perioperative setting. It is frequently combined with opiates to allow for synergism, or it can be used as a sole analgesic to provide up to 4 hours of relief for moderate pain. While acetaminophen's main role as a multimodal analgesic regimen has been in tablet form as an opioid/acetaminophen combination in the post- anesthesia care unit (PACU), acetaminophen has emerged as an important perioperative analgesic due to FDA approval of an intravenous (IV) formulation (Ofirmev®) in the United States in 2010. While the new intravenous formulation was approved based upon its postoperative effectiveness and safety, there is also an interest in its preoperative use. [12, 13] The benefit IV acetaminophen claims over the oral modality is a 70% higher blood concentration than a single similar dose (1 gram) of oral acetaminophen and a rapid onset with peak blood concentration within 15 minutes of infusion while similar oral doses may take 90 minutes to reach peak plasma concentrations. Many studies have compared the IV formulation of acetaminophen (Ofirmev®) with the oral formulation at the same dose of 1 gram. However, this does not take into account the difference in pharmacokinetics of oral and intravenous formulations. A 15-minute constant infusion of 1 gram acetaminophen resulted in an average plasma concentration of 25.02 μg/ml at the end of the infusion with subsequent decline to approximately 11 μg/ml at 1 hour and 7 μg/ml at 3 hour after the start of infusion. Pain scores were lowest at one hour but remained significantly low for at least three hours. [FDA med review] Moreover, the pharmacokinetics of the immediate release oral formulation of acetaminophen are well-known. The absorption half life for acetaminophen in healthy subjects ranges from 0.06-0.7 hours (8). The relative bioavailability ranges from 85% to 98%. Moreover, it has a low first pass metabolism with a hepatic extraction ratio of 0.11 to 0.37 (9). After oral administration of 1 gram acetaminophen in the immediate release formulation (IR), peak concentrations of acetaminophen in adults ranged from 7.7 to 17.6 μg/mL within 1 hour.
Although the therapeutic range for acetaminophen is not well established, plasma concentrations of 10-20 mcg/ml are associated with antipyretic activity, and previous work has assumed that antipyretic and analgesic doses will be similar. (3-4). However, another study developed two compartmental pharmacokinetic/pharmacodynamic models to relate plasma concentration to pain score relationship in children who received oral acetaminophen 30 minutes before outpatient tonsillectomy. The model demonstrated only a one point decrease in pain score when the concentration increased from 10 μg/mL to 20 μg/mL and a steep loss of pain protection when the concentration fell below 6 - 7 μg/mL. Therefore, this study indicates a saturation of the analgesic effect of acetaminophen at a threshold plasma concentration of as low as 7 μg/mL.
The basis for our proposal stems from a recent study by J Van Der Westhuizen, et al. They set out to determine if the traditional one gram unit dose reached adequate serum concentrations of greater than 10 mcg/ml. They compared 1 gram each of intravenous (IV) and oral acetaminophen to see if one or both achieved therapeutic plasma concentrations peri-operatively and for how long. This study questioned the use of oral acetaminophen at 1 gram because if it was not achieving therapeutic concentrations, the patients were not getting optimal care (5). From this study, they were able to extrapolate oral doses of 20 mg/kg that would achieve a maximum concentration of 19 mcg/ml (which is the median maximum concentration achieved by IV acetaminophen). The study concluded that for subjects over 75 kg, an effective IV equivalent oral acetaminophen dose would be 1.5 grams or even 2 grams if the subject exceeded 100 kg (5). This study further recommended a follow up study to evaluate these higher doses of oral acetaminophen as it relates to pain scores and rescue medications postoperatively compared to the IV dose of 1 gram. The current unit dose of oral acetaminophen is 1 gram every 6 hours. However, many studies have evaluated the effects of higher doses of oral acetaminophen as well (10, 11). One study supported the use of 5-6 grams of acetaminophen in a 24- hour period in order to reduce requirements for postoperative morphine. requirements (6). Another study measured serum and CSF concentrations one hour after administration of 500 mg, 1 gm, 1.5 gm, or 2 gm of oral acetaminophen (7).
In summary, the investigator's hypothesis is that while a similar dose is less effective, a 1.5 gram dose of oral acetaminophen (as determined by the extrapolation of maximum serum concentrations from the Van Der Westhuizen, et al. study (5)) may be as effective as 1.0 gram of IV acetaminophen in reducing postoperative pain scores and total opioid consumption, thus resulting in lower cost to the patient and provider.
II. Specific Aims:
The investigator's aim is to compare the effects of a 1.5 gram oral acetaminophen to 1 gram IV acetaminophen when given preoperatively to patients undergoing arthroscopic rotator cuff repair by a single surgeon at a single facility. The primary outcomes will evaluate total opioid consumption in the post anesthesia care unit PACU and nominal pain scores. The investigators theorize that 1.5 grams of oral acetaminophen will be as efficacious as 1 gram IV acetaminophen resulting in lower costs to the patient and provider.
- Conditions
- Pain, Postoperative
- Being tested
- IV acetaminophen, oral acetaminophen
- Keywords
- oral acetaminophen, IV acetaminophen, Ofirmev, equianalgesic, arthroscopic rotator cuff repair
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IV acetaminophenDrug
Also called Ofirmev
Ofirmev will be given 15 minutes prior to going to the OR
oral acetaminophenDrug
Also called tylenol
oral acetaminophen will be given preoperatively
| Study group | Role | What they receive |
|---|---|---|
| Group I: IV acetaminophen | Active comparator | Group I will receive 1 gram IV acetaminophen 15 minutes prior to going to the operating room for arthroscopic rotator cuff repair Receives: Drug: IV acetaminophen |
| group 2 | Active comparator | Group 2 will receive 1.5grams of oral acetaminophen immediately prior to proceeding to the operation groom for arthroscopic rotator cuff surgery Receives: Drug: oral acetaminophen |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary outcome will measure total opioid consumption while the patient is in the PACU
opioid consumption will be evaluated by the postoperative nurses who are blinded to the study groups
Measured: From arrival in the recovery room until discharged from the recovery to home, which is an estimated time period of 2 hours
Secondary outcomes (1)
time from PACU admission to request for first opioid dose
post operative nurses will record time to request for first opioid
Measured: from admission into the recovery room until the patient is discharged to home which is an estimated average of 2 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2012 (estimated)
- Study startDec 2015
- Primary completionDec 2016 (estimated)
- Study completionDec 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pain, PostoperativeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 114 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Babiash, Kimberly H., M.D.
- Responsible party
- Sponsor
- Investigators
- Kimberly H Babiash, MD, Principal investigator
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01711229
- Sponsor's protocol ID
- Ofirmev
- Status last verified
- Jan 2015
- First submitted
- 17 Oct 2012
- Last updated
- 28 Jan 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Jan 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Randomized Equivalence Trial Comparing the Analgesic Efficacy of Ofirmev® Compared to a 1.5 Gram Dose of Oral Acetaminophen for Arthroscopic Rotator Cuff Repair
- ClinicalTrials.gov ID
- NCT01711229
- Acronym / sponsor ID
- Ofirmev
- Conditions
- Pain, Postoperative
- Keywords
- oral acetaminophen, IV acetaminophen, Ofirmev, equianalgesic, arthroscopic rotator cuff repair
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 114 participants (estimated)
- Lead sponsor
- Babiash, Kimberly H., M.D.
- Study start
- Dec 2015
- Primary completion
- Dec 2016 (estimated)
- Study completion
- Dec 2016 (estimated)
- First posted
- 22 Oct 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acetaminophen (Tylenol) is a drug that is used commonly for relief of mild to moderate pain. It is found in many pain medicines that people take after having surgery. Narcotics are other drugs also used for pain (examples of narcotics are morphine and related pain medications). Medical science knows for a fact that acetaminophen works well when taken with narcotics for moderate to severe pain. Recently, acetaminophen has become available in an intravenous (IV) form called Ofirmev®. The IV form means that acetaminophen can be given into a vein. The benefits of getting medicine from an IV include:
- making the medicine work quickly
- less medicine having to pass through the liver to be changed into a form that your body can process The investigators know that acetaminophen is helpful for pain relief at the time of surgery and after surgery. Acetaminophen is a very popular drug in outpatient surgery for pain control when patients go home. The patient's surgeon uses it to control pain after surgery at home in the form of Lortab or Percocet (Lortab and Percocet also have a narcotic medicine that mixes with acetaminophen). Also, currently at Surgicare, some anesthesiologists give intravenous acetaminophen while the patient is waiting to go to surgery. The investigators currently do not give any patient acetaminophen by mouth BEFORE surgery. However, since the addition of the IV form to the drug market, there has been interest to see if the oral form is just as good or better in reducing pain after surgery. This is why we are asking patients to join our study. The goal of this study is to find out if the oral form (by mouth) or the IV form (given into a vein) of acetaminophen controls pain after surgery better.
Detailed description
The American Society of Anesthesiologists recommends acetaminophen, NSAIDS, or COX-2 inhibitors as part of a multimodal pain management strategy to limit opioid usage (1). As the surgical patient population becomes more complex with comorbidities ranging from obesity, obstructive sleep apnea , and asthma becoming more common, the medical community continues to search for efficacious analgesics with a high safety profile. While non-steroidal anti-inflammatory drugs play an important role in multi-modal analgesia, their use is limited based on concerns for platelet inhibition, asthma exacerbation, and renal artery perfusion in patients of advanced age or reduced creatinine clearance.
Acetaminophen has proven to be an important analgesic in the perioperative setting. It is frequently combined with opiates to allow for synergism, or it can be used as a sole analgesic to provide up to 4 hours of relief for moderate pain. While acetaminophen's main role as a multimodal analgesic regimen has been in tablet form as an opioid/acetaminophen combination in the post- anesthesia care unit (PACU), acetaminophen has emerged as an important perioperative analgesic due to FDA approval of an intravenous (IV) formulation (Ofirmev®) in the United States in 2010. While the new intravenous formulation was approved based upon its postoperative effectiveness and safety, there is also an interest in its preoperative use. [12, 13] The benefit IV acetaminophen claims over the oral modality is a 70% higher blood concentration than a single similar dose (1 gram) of oral acetaminophen and a rapid onset with peak blood concentration within 15 minutes of infusion while similar oral doses may take 90 minutes to reach peak plasma concentrations. Many studies have compared the IV formulation of acetaminophen (Ofirmev®) with the oral formulation at the same dose of 1 gram. However, this does not take into account the difference in pharmacokinetics of oral and intravenous formulations. A 15-minute constant infusion of 1 gram acetaminophen resulted in an average plasma concentration of 25.02 μg/ml at the end of the infusion with subsequent decline to approximately 11 μg/ml at 1 hour and 7 μg/ml at 3 hour after the start of infusion. Pain scores were lowest at one hour but remained significantly low for at least three hours. [FDA med review] Moreover, the pharmacokinetics of the immediate release oral formulation of acetaminophen are well-known. The absorption half life for acetaminophen in healthy subjects ranges from 0.06-0.7 hours (8). The relative bioavailability ranges from 85% to 98%. Moreover, it has a low first pass metabolism with a hepatic extraction ratio of 0.11 to 0.37 (9). After oral administration of 1 gram acetaminophen in the immediate release formulation (IR), peak concentrations of acetaminophen in adults ranged from 7.7 to 17.6 μg/mL within 1 hour.
Although the therapeutic range for acetaminophen is not well established, plasma concentrations of 10-20 mcg/ml are associated with antipyretic activity, and previous work has assumed that antipyretic and analgesic doses will be similar. (3-4). However, another study developed two compartmental pharmacokinetic/pharmacodynamic models to relate plasma concentration to pain score relationship in children who received oral acetaminophen 30 minutes before outpatient tonsillectomy. The model demonstrated only a one point decrease in pain score when the concentration increased from 10 μg/mL to 20 μg/mL and a steep loss of pain protection when the concentration fell below 6 - 7 μg/mL. Therefore, this study indicates a saturation of the analgesic effect of acetaminophen at a threshold plasma concentration of as low as 7 μg/mL.
The basis for our proposal stems from a recent study by J Van Der Westhuizen, et al. They set out to determine if the traditional one gram unit dose reached adequate serum concentrations of greater than 10 mcg/ml. They compared 1 gram each of intravenous (IV) and oral acetaminophen to see if one or both achieved therapeutic plasma concentrations peri-operatively and for how long. This study questioned the use of oral acetaminophen at 1 gram because if it was not achieving therapeutic concentrations, the patients were not getting optimal care (5). From this study, they were able to extrapolate oral doses of 20 mg/kg that would achieve a maximum concentration of 19 mcg/ml (which is the median maximum concentration achieved by IV acetaminophen). The study concluded that for subjects over 75 kg, an effective IV equivalent oral acetaminophen dose would be 1.5 grams or even 2 grams if the subject exceeded 100 kg (5). This study further recommended a follow up study to evaluate these higher doses of oral acetaminophen as it relates to pain scores and rescue medications postoperatively compared to the IV dose of 1 gram. The current unit dose of oral acetaminophen is 1 gram every 6 hours. However, many studies have evaluated the effects of higher doses of oral acetaminophen as well (10, 11). One study supported the use of 5-6 grams of acetaminophen in a 24- hour period in order to reduce requirements for postoperative morphine. requirements (6). Another study measured serum and CSF concentrations one hour after administration of 500 mg, 1 gm, 1.5 gm, or 2 gm of oral acetaminophen (7).
In summary, the investigator's hypothesis is that while a similar dose is less effective, a 1.5 gram dose of oral acetaminophen (as determined by the extrapolation of maximum serum concentrations from the Van Der Westhuizen, et al. study (5)) may be as effective as 1.0 gram of IV acetaminophen in reducing postoperative pain scores and total opioid consumption, thus resulting in lower cost to the patient and provider.
II. Specific Aims:
The investigator's aim is to compare the effects of a 1.5 gram oral acetaminophen to 1 gram IV acetaminophen when given preoperatively to patients undergoing arthroscopic rotator cuff repair by a single surgeon at a single facility. The primary outcomes will evaluate total opioid consumption in the post anesthesia care unit PACU and nominal pain scores. The investigators theorize that 1.5 grams of oral acetaminophen will be as efficacious as 1 gram IV acetaminophen resulting in lower costs to the patient and provider.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group I: IV acetaminophen | Active comparator | Drug: IV acetaminophenGroup I will receive 1 gram IV acetaminophen 15 minutes prior to going to the operating room for arthroscopic rotator cuff repair |
| group 2 | Active comparator | Drug: oral acetaminophenGroup 2 will receive 1.5grams of oral acetaminophen immediately prior to proceeding to the operation groom for arthroscopic rotator cuff surgery |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥18
- Weight 75kg -120 kg
- Undergoing arthroscopic rotator cuff repair by same surgeon at Surgicare of Wichita
- Patients who sign informed consent
- Patients who do not meet any of the exclusion criteria
Key exclusion criteria (17 listed)
- Age < 18 yrs (will reduce risk of overdosing oral acetaminophen)
- History of opioid abuse or chronic opioid use greater than 3 months (may skew data with regards to pain control due to the concept of tolerance)
- Acetaminophen allergy (avoids risk of allergic reaction)
- Liver disease as determined by anesthesiologist by history (acetaminophen involves the liver for metabolism, therefore, if the liver is not functioning appropriately, doses could accumulate and cause damage.)
- Daily alcohol consumption (same explanation as for liver disease)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IV acetaminophenAlso: OfirmevOfirmev will be given 15 minutes prior to going to the OR | Drug | Group I: IV acetaminophen |
| oral acetaminophenAlso: tylenoloral acetaminophen will be given preoperatively | Drug | group 2 |
Primary outcome
Primary outcome will measure total opioid consumption while the patient is in the PACU
Time frame: From arrival in the recovery room until discharged from the recovery to home, which is an estimated time period of 2 hours
opioid consumption will be evaluated by the postoperative nurses who are blinded to the study groups
1 secondary outcome
time from PACU admission to request for first opioid dose
Time frame: from admission into the recovery room until the patient is discharged to home which is an estimated average of 2 hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jan 2015.
Related trials for Pain, Postoperative
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Active, not recruitingPhase 4
Effect of Dexmedetomidine on Postoperative Pain in Spinal Anesthesia for Cesarean Section at Assuit University Hospital
Cesarean Section
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kimberly H Babiash, MD principal investigator
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing IV acetaminophen and oral acetaminophen in people with Pain, Postoperative, run by Babiash, Kimberly H., M.D. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Kimberly H Babiash, MD (806-543-6589, kbabiash@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary outcome will measure total opioid consumption while the patient is in the PACU (time frame: From arrival in the recovery room until discharged from the recovery to home, which is an estimated time period of 2 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2015; AzTrials last refreshed its copy on 6 Nov 2026.